Rucaparib (AG-014699) phosphate

For research use only. Not for use in humans.

製品コードS1098 別名：PF-01367338

CAS No. 459868-92-9

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

サイズ

価格(税別)

10mM (1mL in DMSO)	JPY 24200
5mg	JPY 21900
10mg	JPY 36800
50mg	JPY 113200

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(93)

製品安全説明書

PARP阻害剤の選択性比較

生物活性

製品説明

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

特性

The first PARP inhibitor used in clinical trials combined with temozolomide.

ターゲット

PARP ^[1]
(Cell-free assay)

1.4 nM(Ki)

体外試験

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. ^[1] ^[2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. ^[3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. ^[4]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
BT-474	MV7GeY5kfGmxbjDBd5NigQ>?	NV7JbZpDOC5zL{GvOVAxNzFyMECgcm0>			MVTpcohq[mm2czDQRXJRKGGldHn2bZR6KGG2IIP0ZZJ1cW6pIHPvcoNmem62cnH0bY9vKG:oIEWwNEBvVQ>?	NHjmeHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyPFQ2PSd-MkWxNlg1PTV:L3G+
BT474	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3ThN\|UxOCCwTR?=	NGrJd3EyOOLCk{G1xsBl		MXvy[YR2[2W\|IHPlcIwh\3Kxd4ToJIlvKHSqZTDmc5VzKGyrbnXzJIFv\CC\|aXfubYZq[2GwdHz5	MnnCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMki0OVUoRjJ3MUK4OFU2RC:jPh?=
SKBR3	NXT3OnJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TDSFUxOCCwTR?=	MoWzNVDjiJNzNdMg[C=>		NI\BR2Rz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIITo[UBnd3W{IHzpcoV{KGGwZDDzbYdvcW[rY3HueIx6	NGTVT4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyPFQ2PSd-MkWxNlg1PTV:L3G+
AU565	NX7GXWdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXNdGo2ODBibl2=	M2LzSVEx6oDVMUZCpIQ>		Mn:0doVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=>	NXXUVnNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlg1PTVpPkK1NVI5PDV3PD;hQi=>
EFM192A	NWjNNnBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\NNlUxOCCwTR?=	MWGxNQKBmzF3wrDk		MmPydoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=>	NF3SSZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyPFQ2PSd-MkWxNlg1PTV:L3G+
MDA-MB-231	MlfWSpVv[3Srb36gRZN{[Xl?	MXOxNE8zOC92MDFOwG0>	NYftWXlvOjRiaB?=		NETESI9qdmO{ZXHz[ZMheC2DS2SgcIV3\Wy\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{MEG1Nkc,OjR2MkCxOVI9N2F-
MDA-MB-231	M1vGTWNmdGxiVnnhZoltcXS7IFHzd4F6	M2DDN\|AvOS12MDFOwG0>	Mor3NlQhcA>?		MljNTWM2OOLCiU5ihKkyPy55N9Mg{txO	MoXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkCxOVIoRjJ2NEKwNVUzRC:jPh?=
MDA-MB-231	NUfJXmdESXCxcITvd4l{KEG\|c3H5	MVKxNE8zOC92MDFOwG0>	NVXmZZhnOjRiaB?=		NW\xO5I2cW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	MofhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkCxOVIoRjJ2NEKwNVUzRC:jPh?=
MDA-MB-231	MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlf6NVAwOjBxNECg{txO	NXvTXFR1OjRiaB?=		MlvkZoxw[2u\|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hcW5iR{KvUUBxcGG\|ZR?=	NV3rRpdsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlAyPTJpPkK0OFIxOTV{PD;hQi=>
H460	MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHBOFAxKG6P	Mnz6NlTDqGh?		MX7pcoNz\WG\|ZYOgZ4VtdHWuYYKgdoFlcW:\|ZX7zbZRqfmm2eR?=	M4\GSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEGxOlEyLz5{NESxNVYyOTxxYU6=
A549	NYPvNXdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjCOFAxKG6P	NGe2ZYEzPMLiaB?=		NXnWPIk6cW6lcnXhd4V{KGOnbHz1cIFzKHKjZHnvd4Vve2m2aY\peJk>	NGDjbVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxNVYyOSd-MkS0NVE3OTF:L3G+
DT40	M1vqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmX5TWM2OD1{MTDuUS=>	Mlf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NU[4NVMoRjJ2M{W2PFE{RC:jPh?=
DU145	MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTF6IH7N	NF;NVJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1OlgyOyd-MkSzOVY5OTN:L3G+
COLO704	NG\VW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TafGlEPTB;Mj61NkDDuSByLk[3JO69VQ>?	NGnTNZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVMANAb	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkiyTWM2OD1{LkW4JOKyKDBwM{ig{txO	M{XPblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OV177	NVuxV5NjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTBXpBbUUN3ME2yMlc5KMLzIECuO\|Eh\|ryP	MljLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
OAW28	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkS3TWM2OD1\|Lk[xJOKyKDBwMkig{txO	NV7NNZhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
OVSAHO	NWXBVpl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULCZYYxUUN3ME2zMlY1KMLzIECuN\|Mh\|ryP	MmnmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
OVKATE	M2flSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XKdWlEPTB;Mz62OEDDuSBzLke5JO69VQ>?	NFTsU4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVCAR3	M{fh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3P5OmlEPTB;Mz63OEDDuSByLkSwJO69VQ>?	MmrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
PEO14	MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nlOWlEPTB;Mz64OEDDuSByLke2JO69VQ>?	NXTtNFVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
A2780	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moi0TWM2OD1\|Lkm0JOKyKDBwMkWg{txO	MkG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
OVTOKO	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnvTWM2OD12LkG0JOKyKDFwNUOg{txO	NEC5[Ww9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
KURAMOCHIb	NX:3VmcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTrWmF7UUN3ME20MlM1KMLzIECuNlkh\|ryP	NEHyXVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
TOV21G	M37idWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3pR2ZKSzVyPUWuNFchyrFiMT6zNEDPxE1?	NV\oVG1LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
OVISE	NHLGeZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEn1Z4dKSzVyPUWuOlghyrFiMD6yN{DPxE1?	M4jKSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
KK	NUCydW46T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvjc2NKSzVyPU[uNVUhyrFiMT60NkDPxE1?	NXXpZXdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
RMUGS	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITqW3JKSzVyPUeuNFMhyrFiMT64N{DPxE1?	NELLcHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
PEO6	M4XFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTdwME[gxtEhOC55NDFOwG0>	NV;v[4c2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
OVCA429	Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTSfIFlUUN3ME24MlI6KMLzIEGuOlQh\|ryP	NVToVXBmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
OV167	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWSwbVZlUUN3ME24MlM{KMLzIEGuNVgh\|ryP	M2XlR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
RMG1	NVzWUZhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPEbIhKSzVyPUmuN\|IhyrFiMj6zOkDPxE1?	M2DLN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVCAR5	MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTlwNUCgxtEhOi53OTFOwG0>	M2eyVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
EFO21	NG\qXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnrc5Q{UUN3ME25MlkzKMLzIEGuPFch\|ryP	M{\mdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
ES2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV[zWVV4UUN3ME2xNE4yOiEEsTCxMlI{KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
Tyk-nu	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3SbGNKSzVyPUGwMlIxKMLzIEGuNVIh\|ryP	NEHrUlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
CAOV3	M4fNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfwPZdUUUN3ME2xNE4{PyEEsTCwMlg4KM7:TR?=	M2THfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OV207	M2XvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTF{LkK3JOKyKDBwM{Kg{txO	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
HEY	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXhO3FKSzVyPUGzMlAyKMLzIECuO\|Uh\|ryP	MmOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
DOV13	NYfLW\|JvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHSVIZKSzVyPkG1JO69VQ>?	Mmn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
EFO27	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\abYhKSzVyPkG1JO69VQ>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
HEY C2	NGj6TIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzITZhKSzVyPkG1JO69VQ>?	NXLYRWpKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
KOC-7cc	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRjF3IN88US=>	Mn;jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
MCASb	NFHRTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TE[WlEPTB-MUWg{txO	M{OxN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OAW42	MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHi3[IhKSzVyPkG1JO69VQ>?	NVn5U4I3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
OV2008	NIr5dVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDERoRlUUN3ME6xOUDPxE1?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OV90	NG\Fd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7nTWM2OD5zNTFOwG0>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVCA420b	NXHDbZRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXm4N\|JwUUN3ME6xOUDPxE1?	NXL3c5hWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
OVCA432	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRjF3IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
PEA2	M4fnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlK2TWM2OD5zNTFOwG0>	NVLCU5lwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
SKOV3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfETWM2OD5zNTFOwG0>	M1P1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
TOV112D	NH;pNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfldosxNTNizszN			NITUOVhKSzVyPkG1JO69VQ>?	NV7sfoV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
C4-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvxN5JjOC1\|IN88US=>	NFrhdYIyPCCm	MXnEUXNQ	MU\k[YNz\WG\|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6	NYD0UYZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlUzPDRpPkKzOVY2OjR2PD;hQi=>
PC3	M37oZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVKwMVMh\|ryP	MVGxOEBl	MVTEUXNQ	Mm\P[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NUK0OEc,OjN3NkWyOFQ9N2F-
DU145	NHX3V3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYWwMVMh\|ryP	M1HrdVE1KGR?	MnzwSG1UVw>?	MXzk[YNz\WG\|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6	NILndoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2OVI1PCd-MkO1OlUzPDR:L3G+
VCaP	NITJNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\VcWVmOC1\|IN88US=>	MXqxOEBl	MVjEUXNQ	NX\sRmxb\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?=	M1\xWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[1NlQ1Lz5{M{W2OVI1PDxxYU6=
LNCaP	NHjhc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzLW3UyOC1\|IN88US=>	NYrmRnZKOTRiZB?=	M2[2bGROW09?	MV\k[YNz\WG\|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6	MlGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkWyOFQoRjJ\|NU[1NlQ1RC:jPh?=
MDA-MB-468	NYTMNmllS2WubDDWbYFjcWyrdImgRZN{[Xl?				NF24TWJKSzVyPUmuO{DPxE1?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ5OEG2NUc,OjJ4N{ixOlE9N2F-
MDA-MB-231	MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>				M3frVmlEPTB;MUOg{txO	MljaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4N{ixOlEoRjJ{Nke4NVYyRC:jPh?=
Cal-51	MnTjR4VtdCCYaXHibYxqfHliQYPzZZk>				MmXRTWM2OD16Lk[g{txO	M{\uVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Nke4NVYyLz5{Mk[3PFE3OTxxYU6=
LoVo	MkXySpVv[3Srb36gZZN{[Xl?		MXqzNEBucW6\|		NVr5b\|ZxUW6qaXLpeIlwdiCxZjDQRXJRKGmwIHj1cYFvKEyxVn:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyb3z5LGFFWClvcnnic5NmKHCxbInt[ZJqgmG2aX;uJIZweiB\|MDDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygSWM2OCB;IECuNFA1PjlizszNMi=>	M4DYSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO\|E4Lz5{Nk[1NlcyPzxxYU6=
MX1	NWnh[XJlS3m2b4TvfIlkcXS7IHHzd4F6				MlT1R5l1d3SxeHnjbZR6KGGpYXnud5QhSlKFQUGt[IVncWOrZX70JIh2dWGwIF3YNUBk\WyuczygSWM2OCB;IECuNFA2OyEQvF2u	NI\hT2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
Rosetta2 (DE3)	M1LMdmZ2dmO2aX;uJIF{e2G7				M2ewfGlvcGmkaYTpc44hd2ZiaIXtZY4hVi22ZYLtbY5idCB4eHjpd{11[WepZXSgRXJVTDZiKEi3N{B1dyBzMU[xLUBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCUb4PleJRiOiBqRFWzLUBk\WyuczD1d4lv\yCQQVSrJIF{KHO3YoP0doF1\SCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCwMlAyPCEQvF2u	NV;3fndsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4PzBpPkK0PVAxPzdyPD;hQi=>
Rosetta2 (DE3)	NXvQUnJMTnWwY4Tpc44h[XO\|YYm=				MUHJcohq[mm2aX;uJI9nKGi3bXHuJFZ5cGm\|LYTh[4dm\CCDUmTEOUApOTB\|MDD0c{AyOzF5KTDlfJBz\XO\|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBTd3OndIThNkApTEV\|KTDj[YxteyC3c3nu[{BPSURtIHHzJJN2[nO2cnH0[UBjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCyOUDPxE1w	Ml[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3O\|AoRjJ2OUCwO\|cxRC:jPh?=
LoVo	M1vyR2N6fG:2b4jpZ4l1gSCjc4PhfS=>	MUewMlQhfU1?	NV\BZ\|R{PSCmYYnz		MmTmVI91\W62aXH0bY9vKG:oIITlcY97d2yxbXnk[U1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCrbjDoeY1idiCOb2\vJINmdGy\|IHHzd4V{e2WmIHHzJJRmdW:8b3zvcYll\SCJSUWwJIF1KDBwNDD1UUBi\nSncjC1JIRigXNiYomgR4VtdHSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvOTR2IN88UU4>	Mk\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO\|E4RC:jPh?=
Capan1	MkLER5l1d3SxeHnjbZR6KGG\|c3H5				NYi0fFQ6S3m2b4TvfIlkcXS7IHHnZYlve3RiQmLDRVIu\GWoaXPp[Y51KGi3bXHuJGNieGGwMTDj[YxteyxiRVO1NEA:KDBwNkC5JO69VS5?	M2G4NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO\|E4Lz5{Nk[1NlcyPzxxYU6=
MDA-MB-436	MVfBcpRq[2GwY3XyJIF{e2G7		MnL6PVYhcHK\|		NEX4dplCdnSrY3HuZ4VzKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRnJESTFvZHXmbYNq\W62IF3ERU1OSi12M{[gZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NEA:KDNizszNMi=>	NUTDPIlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOFI5PjhpPkK2N\|QzQDZ6PD;hQi=>
OVCAR3	M2C1OWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mmr5NlQhcHK\|		NVrTSYlOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDPWmNCWjNiY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFMvOzFizszNMi=>	NV7tdYZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVYyODZpPkK5OFU3OTB4PD;hQi=>
MRC5	NXTyWYNRS3m2b4TvfIlkcXS7IHHzd4F6				NIPBR5REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOWkN3IHPlcIx{NCCHQ{WwJF0hQC53MzFOwG0v	NHnqe3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MCF7	MYXBcpRq[2GwY3XyJIF{e2G7		NHnYVpE6PiCqcoO=		M17hW2FvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO\|YYmsJGNEPTBiPTCxPU41PyEQvF2u	Ml7TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NEK4OlgoRjJ4M{SyPFY5RC:jPh?=
A673	NV76TY0xeUiWUzDhd5NigQ>?				NHPSc5pyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	MkL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	M{PQdJFJXFNiYYPzZZk>				NFT3RZdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	NVvPVFFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	MW\xTHRUKGG\|c3H5				NW\DbGZTeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MoX3dWhVWyCjc4PhfS=>				MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{	NHvwe3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	MnzKdWhVWyCjc4PhfS=>				M{Tt[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	PAR; PubMed: 27960087 Cancer Cell MCF-7 cells were pretreated ± Rucaparib (15 µM, 2 hr), then ± Rucaparib (15 µM) or two different doses of β-lap (2.0 or 5.0 µM) for 2 hr. Levels of PAR (PARP hyperactivation) formation were assessed with α-tubulin as loading controls. BRCA1; PubMed: 24085845 Proc Natl Acad Sci U S A MCF7 cells, MDA-MB-436 parental cells and resistant clones RR-1, RR-5, and RR-6 were treated with DMSO (−) or 1 µM rucaparib (+) for 24 h, and BRCA1 protein levels were assessed by using BRCA1 N- or C-terminal-specific antibodies by Western blot.	27960087 24085845
Growth inhibition assay	Cell viability; PubMed: 31119062 Adv Wound Care (New Rochelle) The effect of rucaparib on proliferation of keloid fibroblasts. (A) Keloid cell growth following treatment with rucaparib at various concentration (0, 2, 10, 20 μM) was evaluated by MTT assays. Data are expression as mean standard deviation of percent changes of triplicate optical densities. (B) Rucaparib (20 μM) significantly decreased proliferation of keloid fibroblasts. The combination of rucaparib (20 μM) and triamcinolone (50 μM) showed additive suppressive effect on keloid fibroblasts as compared with rucaparib single therapy. Data are expression as mean standard deviation of percent changes of triplicate optical densities. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.	31119062
Immunofluorescence	α-tubulin; PubMed: 30589644 J Clin Invest Representative immunofluorescence images of DMSO-, rucaparib- (Ruca-), and Ola-exposed A549-ERCC1(WT/WT) and A549-ERCC1(–/–) cells. Cells were exposed to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bar: 20 μm. PAR; PubMed: 27515310 BMC Cancer Cells were treated with 20 mM hydrogen peroxide (H2O2) in order to stimulate PARP-1 activity in the presence or absence of the PARP-1 inhibitors rucaparib and olaparib. Poly(ADP-ribose) (PAR) chain synthesis was detected using an anti-PAR monoclonal Alexa Fluor 488-conjugated antibody (green). The nucleus was visualised using the nuclear counterstain DAPI (blue). Representative images obtained from the analysis of anti-PAR staining of SK-N-BE(2c) cells are shown. γH2AX; PubMed: 23565244 PLoS One γH2AX foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells. 53BP1; PubMed: 23565244 PLoS One 53BP1 foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells.	30589644 27515310 23565244

体内試験

Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. ^[4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. ^[5]

お薦めの試験操作（参考用のみ）

キナーゼ試験：^[1]	- 合併 K_i Determination: Inhibition of human full-length recombinant PARP-1 by [³²P]NAD⁺ incorporation is measured. The [³²P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. K_i is calculated by nonlinear regression analysis.
細胞試験： ^[4]	- 合併細胞株： D425Med, D283Med and D384Med cells 濃度： 0.4 μM 反応時間： 3 or 5 days 実験の流れ： Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 10³, 3 × 10³ and 3 × 10³, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone. (参考用のみ)
動物試験：^[4]	- 合併動物モデル： CD-1 nude mice bearing established D283Med xenografts 投薬量： 1 mg/kg 投与方法： One or four daily by i.p. (参考用のみ)

参考

- 合併

溶解度 (25°C)

体外	DMSO	84 mg/mL (199.35 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 2% DMSO+30% PEG 300+2% Tween 80+ddH2O 混合させたのち直ちに使用することを推奨します。	10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Rucaparib (AG-014699) phosphate SDFをダウンロードする

分子量	421.36
化学式	C₁₉H₁₈FN₃O.H₃PO₄
CAS No.	459868-92-9
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	PF-01367338
Smiles	CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04539327	Recruiting	Drug: Rucaparib	Epithelial Ovarian Cancer\|Fallopian Tube Cancer\|Primary Peritoneal Cancer	Grupo Español de Investigación en Cáncer de Ovario\|Clovis Oncology Inc.	July 29 2020	--
NCT04179396	Recruiting	Drug: Rucaparib\|Drug: Enzalutamide\|Drug: Abiraterone	Metastatic Castration Resistant Prostate Cancer	Clovis Oncology Inc.	December 5 2019	Phase 1
NCT04171700	Recruiting	Drug: Rucaparib	Solid Tumor	Clovis Oncology Inc.	November 21 2019	Phase 2
NCT03954366	Active not recruiting	Drug: Rucaparib\|Drug: Rosuvastatin\|Drug: Oral Contraceptives	Neoplasms	Clovis Oncology Inc.	May 8 2019	Phase 1
NCT03824704	Terminated	Drug: Rucaparib\|Drug: Nivolumab	Epithelial Ovarian Cancer\|Fallopian Tube Cancer\|Primary Peritoneal Carcinoma\|High Grade Serous Carcinoma\|Endometrioid Adenocarcinoma	Clovis Oncology Inc.\|Bristol-Myers Squibb\|Foundation Medicine	May 15 2019	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

PARPシグナル伝達経路

PARP Inhibitors with Unique Features

Selective PARP Inhibitors

AG-14361 : PARP1-selective, K_i<5 nM.
Selective PARP Inhibitors

UPF 1069 : PARP2-selective, IC50=0.3 μM.
Most Potent PARP Inhibitor

MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.
PARP Inhibitor in Clinical Trial

Iniparib (BSI-201) : Phase III for solid tumors.
Newest PARP Inhibitor

PJ34 HCl ^New : PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

相関PARP製品

G007-LK

G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.
NU1025

NU1025 (NSC 696807) is a potent PARP inhibitor with IC50 of 400 nM.
SCR7

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).
Olaparib (AZD2281)

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations.

Features:A potent PARP inhibitor (currently in late stage clinical trials).
Veliparib (ABT-888)

Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.

Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Talazoparib (BMN 673)

Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Features:Most potent and selective PARPi reported thus far.
Iniparib (BSI-201)

Iniparib (BSI-201, NSC-746045, IND-71677) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.

研究分野別

製品類型

Rucaparib (AG-014699) phosphate

文献中Selleckの製品使用例(93)

製品安全説明書

PARP阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Rucaparib (AG-014699) phosphate SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-01-06)

技術サポート

PARPシグナル伝達経路

PARP Inhibitors with Unique Features

相関PARP製品